Follow
György M. Keserű
György M. Keserű
Verified email at ttk.mta.hu - Homepage
Title
Cited by
Cited by
Year
Encyclopedia of Pharmaceutical Technology: Volume 6
J Swarbrick
CRC press, 2013
17602013
The role of ligand efficiency metrics in drug discovery
AL Hopkins, GM Keserü, PD Leeson, DC Rees, CH Reynolds
Nature reviews Drug discovery 13 (2), 105-121, 2014
8762014
The influence of lead discovery strategies on the properties of drug candidates
GM Keserü, GM Makara
nature reviews Drug Discovery 8 (3), 203-212, 2009
6292009
Finding the sweet spot: the role of nature and nurture in medicinal chemistry
MM Hann, GM Keserü
Nature reviews Drug discovery 11 (5), 355-365, 2012
3962012
Expanding the medicinal chemistry synthetic toolbox
J Boström, DG Brown, RJ Young, GM Keserü
Nature Reviews Drug Discovery 17 (10), 709-727, 2018
3492018
Hit discovery and hit-to-lead approaches
GM Keserű, GM Makara
Drug discovery today 11 (15-16), 741-748, 2006
3482006
Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease
A Douangamath, D Fearon, P Gehrtz, T Krojer, P Lukacik, CD Owen, ...
Nature communications 11 (1), 1-11, 2020
2922020
Design principles for fragment libraries: maximizing the value of learnings from pharma fragment-based drug discovery (FBDD) programs for use in academia
GM Keserű, DA Erlanson, GG Ferenczy, MM Hann, CW Murray, ...
Journal of medicinal chemistry 59 (18), 8189-8206, 2016
1832016
GPCRdb in 2021: integrating GPCR sequence, structure and function
AJ Kooistra, S Mordalski, G Pándy-Szekeres, M Esguerra, A Mamyrbekov, ...
Nucleic Acids Research 49 (D1), D335-D343, 2021
1772021
Impact of lipophilic efficiency on compound quality
A Tarcsay, K Nyíri, GM Keserű
Journal of medicinal chemistry 55 (3), 1252-1260, 2012
1612012
Thermodynamics guided lead discovery and optimization
GG Ferenczy, GM Keserű
Drug discovery today 15 (21-22), 919-932, 2010
1382010
A high throughput luminescent assay for glycogen synthase kinase-3 β inhibitors
A Baki, A Bielik, L Molnár, G Szendrei, GM Keserü
Assay and drug development technologies 5 (1), 75-84, 2007
1352007
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods
GM Keserü
Bioorganic & medicinal chemistry letters 13 (16), 2773-2775, 2003
1282003
Contributions of molecular properties to drug promiscuity: miniperspective
Á Tarcsay, GM Keserű
Journal of medicinal chemistry 56 (5), 1789-1795, 2013
1272013
Recent advances in the prediction of blood–brain partitioning from molecular structure
M Lobell, L Molnár, GM Keserü
Journal of pharmaceutical sciences 92 (2), 360-370, 2003
1272003
Fully flexible low-mode docking: application to induced fit in HIV integrase
GM Keserű, I Kolossváry
Journal of the American Chemical Society 123 (50), 12708-12709, 2001
1182001
Pharmacologic inhibition of STAT5 in acute myeloid leukemia
B Wingelhofer, B Maurer, EC Heyes, AA Cumaraswamy, A Berger-Becvar, ...
Leukemia 32 (5), 1135-1146, 2018
1122018
Discovery of novel human histamine H4 receptor ligands by large-scale structure-based virtual screening
R Kiss, B Kiss, Á Könczöl, F Szalai, I Jelinek, V László, B Noszál, A Falus, ...
Journal of medicinal chemistry 51 (11), 3145-3153, 2008
1122008
In silico and ex silico ADME approaches for drug discovery
F Darvas, G Keseru, A Papp, G Dorman, L Urge, P Krajcsi
Current topics in medicinal chemistry 2 (12), 1287-1304, 2002
1072002
Virtual screening for β-secretase (BACE1) inhibitors reveals the importance of protonation states at Asp32 and Asp228
T Polgár, GM Keserü
Journal of Medicinal Chemistry 48 (11), 3749-3755, 2005
1062005
The system can't perform the operation now. Try again later.
Articles 1–20